Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
RVNC

RVNC - Revance Therapeutics Inc Stock Price, Fair Value and News

3.02USD-0.14 (-4.43%)Delayed

Market Summary

RVNC
USD3.02-0.14
Delayed
-4.43%

RVNC Alerts

  • JPMORGAN CHASE & CO reported owning 2.6% of RVNC [2024-04-09]
  • Losses in recent quarter

RVNC Stock Price

View Fullscreen

RVNC RSI Chart

RVNC Valuation

Market Cap

315.4M

Price/Earnings (Trailing)

-0.99

Price/Sales (Trailing)

1.33

Price/Free Cashflow

-1.43

RVNC Price/Sales (Trailing)

RVNC Profitability

Return on Equity

321.66%

Return on Assets

-62.46%

Free Cashflow Yield

-69.98%

RVNC Fundamentals

RVNC Revenue

Revenue (TTM)

236.6M

Rev. Growth (Yr)

5.28%

Rev. Growth (Qtr)

-25.59%

RVNC Earnings

Earnings (TTM)

-317.4M

Earnings Growth (Yr)

11.03%

Earnings Growth (Qtr)

4.49%

Breaking Down RVNC Revenue

Last 7 days

-9.0%

Last 30 days

-19.7%

Last 90 days

-45.7%

Trailing 12 Months

-90.5%

How does RVNC drawdown profile look like?

RVNC Financial Health

Current Ratio

5.37

Debt/Equity

-4.31

Debt/Cashflow

-0.5

RVNC Investor Care

Shares Dilution (1Y)

24.28%

Diluted EPS (TTM)

-3.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024236.6M000
2023156.6M186.4M214.2M234.0M
202289.8M99.3M108.6M132.6M
202128.6M47.1M63.0M77.8M
20204.1M7.9M11.6M15.3M
20194.3M4.8M5.1M413.0K
20182.4M3.1M4.0M3.7M
20171.2M1.2M963.0K1.7M
2016502.0K777.0K1.0M1.2M
2015252.0K226.0K219.0K219.0K
2014700.0K700.0K617.0K383.0K
2013266.8K383.5K500.3K617.0K
2012000150.0K

Tracking the Latest Insider Buys and Sells of Revance Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 01, 2024
ware olivia c
acquired
-
-
15,000
-
May 01, 2024
russell angus c.
acquired
-
-
15,000
-
May 01, 2024
beraud jill
acquired
-
-
15,000
-
May 01, 2024
nolet chris
acquired
-
-
15,000
-
May 01, 2024
kolaja carey oconnor
acquired
-
-
15,000
-
May 01, 2024
coric vlad
acquired
-
-
15,000
-
May 01, 2024
gangolli julian s
acquired
-
-
15,000
-
Apr 16, 2024
jordan erica
sold
-9,096
3.8028
-2,392
chief commercial officer
Mar 18, 2024
moxie dwight
sold
-40,971
5.0426
-8,125
clo & gc
Mar 18, 2024
schilke tobin
sold
-47,203
5.0426
-9,361
cfo

1–10 of 50

Which funds bought or sold RVNC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
COMERICA BANK
added
29.28
-8,048
21,073
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
9.76
-301,106
479,666
-%
May 16, 2024
JANE STREET GROUP, LLC
added
144
185,657
688,313
-%
May 15, 2024
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)
added
132
288,989
1,252,960
0.09%
May 15, 2024
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
sold off
-100
-38,676
-
-%
May 15, 2024
Palo Alto Investors LP
added
0.2
-20,215,500
25,820,200
2.91%
May 15, 2024
TANG CAPITAL MANAGEMENT LLC
new
-
984,000
984,000
0.10%
May 15, 2024
NOTTINGHAM ADVISORS, INC.
unchanged
-
-46,358
58,937
0.01%
May 15, 2024
MOORE CAPITAL MANAGEMENT, LP
added
66.67
-88,500
1,230,000
0.02%
May 15, 2024
JANUS HENDERSON GROUP PLC
added
0.01
-149,893
189,055
-%

1–10 of 35

Are Funds Buying or Selling RVNC?

Are funds buying RVNC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RVNC
No. of Funds

Unveiling Revance Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 09, 2024
jpmorgan chase & co
2.6%
2,768,691
SC 13G/A
Feb 14, 2024
antara capital lp
0%
0
SC 13G/A
Feb 14, 2024
palo alto investors lp
5.96%
5,237,284
SC 13G/A
Feb 13, 2024
polar capital holdings plc
3.60%
3,169,239
SC 13G/A
Feb 13, 2024
vanguard group inc
5.77%
5,069,625
SC 13G/A
Feb 09, 2024
gic private ltd
6.63%
5,825,881
SC 13G/A
Feb 09, 2024
capital world investors
13.6%
11,939,076
SC 13G/A
Feb 06, 2024
franklin resources inc
6.8%
6,108,277
SC 13G
Jan 25, 2024
jpmorgan chase & co
5.4%
4,754,771
SC 13G/A
Jan 25, 2024
blackrock inc.
8.5%
7,453,371
SC 13G/A

Recent SEC filings of Revance Therapeutics Inc

View All Filings
Date Filed Form Type Document
May 09, 2024
10-Q
Quarterly Report
May 09, 2024
8-K
Current Report
May 03, 2024
8-K
Current Report
May 03, 2024
4
Insider Trading
May 03, 2024
4
Insider Trading
May 03, 2024
4
Insider Trading
May 03, 2024
4
Insider Trading
May 03, 2024
4
Insider Trading
May 03, 2024
4
Insider Trading
May 03, 2024
4
Insider Trading

Peers (Alternatives to Revance Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
50.9B
6.8B
28.49% 6.05%
-8.53
7.44
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
18.9B
2.0B
2.79% -21.33%
-56.9
9.43
75.20% 68.82%
14.7B
2.5B
-14.30% -15.94%
71.65
5.96
13.74% 186.89%
12.8B
3.8B
8.33% -10.25%
17.2
3.4
8.58% 129.81%
MID-CAP
5.6B
107.9M
20.58% 115.45%
-10.31
48.09
54.84% -28.31%
5.0B
524.1M
-13.99% -52.79%
-12.02
9.57
394.93% 39.61%
3.6B
251.0M
9.96% -0.29%
-12.28
14.5
73.58% -86.73%
3.1B
240.7M
9.94% -31.73%
-6.53
12.77
-1.03% -213.43%
2.4B
813.8M
-14.08% -36.34%
-1.4K
3
56.43% 98.83%
SMALL-CAP
1.9B
411.3M
3.06% 35.16%
29.91
4.73
60.38% -34.49%
1.8B
996.6M
233.93% 75.07%
-4.58
1.83
-26.66% 65.49%
480.9M
881.7K
21.10% 351.81%
-14.25
481.06
-77.61% 33.36%
310.9M
4.9M
8.40% 53.85%
-2.49
63.89
-54.97% 48.23%
17.1M
2.1M
4.76% 108.64%
-0.74
7.61
-13.45% 69.54%

Revance Therapeutics Inc News

Latest updates
Defense World15 May 202409:01 am

Revance Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-25.6%51,936,00069,799,00056,776,00058,134,00049,331,00049,921,00029,015,00028,368,00025,261,00025,950,00019,745,00018,804,00013,299,00011,133,0003,835,000299,00058,000693,5001,329,0001,596,0001,570,000
Operating Expenses-20.2%98,763,000123,752,000196,069,000123,633,000107,363,000194,332,000106,499,00086,210,00087,482,00087,554,00092,468,00089,141,00083,311,00089,102,00080,963,00057,404,00061,018,00046,259,00042,586,00039,122,00036,905,000
  S&GA Expenses-19.2%68,914,00085,243,00069,094,00077,384,00066,011,00065,237,00065,775,00047,847,00045,075,00046,436,00052,782,00050,598,00049,005,00052,833,00048,183,00029,606,00021,224,00018,766,00016,739,00013,596,00012,910,000
  R&D Expenses-29.3%14,393,00020,366,00013,060,00022,807,00023,177,00019,541,00026,103,00024,913,00030,729,00029,468,00030,095,00029,441,00027,251,00029,768,00029,130,00027,103,00039,794,00027,493,00025,847,00025,526,00023,995,000
EBITDA Margin---------2.69-3.01-3.49-4.19--9.37-19.55-30.54-22.93-21.17-21.27-22.31-18.66-
Interest Expenses-2.6%5,256,0005,398,0005,093,0004,368,0004,497,0003,752,0006,917,0003,874,0001,931,0001,573,0001,571,0001,569,0001,560,0004,410,0004,334,0004,256,0002,148,000----
Income Taxes---300,000---700,000-------2,720,000--100,000----
Earnings Before Taxes------------74,376,000----81,257,000------
EBT Margin---------3.00-3.31-3.82-4.63--10.27-21.21-32.27-25.01-22.11-21.80-22.86-19.11-
Net Income4.5%-53,200,000-55,699,000-141,176,000-67,318,000-59,793,000-145,952,000-84,693,000-61,435,000-64,342,000-63,098,000-74,376,000-72,197,000-71,639,000-78,309,000-81,257,000-60,590,000-61,933,000-45,326,000-41,409,000-37,390,000-35,304,000
Net Income Margin3.1%-1.34-1.38-1.93-1.92-2.25-2.69-2.52-2.65-3.05-3.62-4.71-6.45---------
Free Cashflow-52.0%-67,651,000-44,510,000-55,465,000-53,116,000-70,370,000-31,470,000-58,873,000-43,689,000-62,726,000-48,968,000-54,169,000-49,985,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets6.2%508478532598548582712562640531582641676720712576593340266296324
  Current Assets9.1%370339389379323375416261285246294355406450450503518297221250277
    Cash Equivalents1.9%14013717914113710911075.0020411613217125333734136528717260.0091.0066.00
  Inventory10.3%50.0046.0046.0034.0028.0018.0017.0014.0011.0010.0010.005.006.006.004.001.00-----
  Net PPE1.6%18.0017.0017.0013.0014.0014.0023.0023.0023.0025.0022.0021.0021.0017.0015.0014.0014.0015.0015.0015.0015.00
  Goodwill----77.0077.0077.00147147147147147147147147145------
Liabilities-3.7%607630639571574569566565614463462455432346339320285115115107103
  Current Liabilities-22.8%69.0089.0082.0074.0078.0076.0075.0077.0071.0067.0066.0058.0051.0061.0064.0048.0042.0041.0034.0045.0034.00
  Long Term Debt-0.4%42542742738038037937937890.00281-----------
    LT Debt, Current100.0%5.003.001.00------------------
    LT Debt, Non Current-100.0%-427427--379---------------
Shareholder's Equity34.9%-98.67-151-27.00-26.6713.001460.0026.0068.001201,4472443743730.000.002251510.00221
  Retained Earnings-2.6%-2,131-2,078-2,000-1,881-1,814-1,754-1,600-1,500-1,500-1,397-1,334-1,260-1,200-1,126-1,050-966-906-844-798-757-720
  Additional Paid-In Capital5.5%2,0331,9271,9161,9081,7881,7671,7551,5211,4881,4661,4551,4471,4321,5011,4211,2221,2141,070950946941
Shares Outstanding18.7%10488.0088.0088.0084.0082.0082.0073.0072.0068.0072.0072.00---------
Float----2,200---1,000---2,000---1,400---494-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-54.3%-65,939-42,731-50,962-53,382-69,500-30,182-57,871-44,225-61,270-44,611-53,167-49,005-74,755-62,314-55,686-17,213-43,289-33,508-31,949-29,290-11,414
  Share Based Compensation1.6%8,9908,84510,28715,59913,08210,72717,9879,26314,36310,92110,53811,36810,60711,87910,6777,3536,5445,0404,3034,4204,159
Cashflow From Investing-1437.9%-31,7092,37051,586-39,53295,31640,960-118,445-105,88144,56827,64116,807-35,693-38,420-8,69132,49693,895-105,56930,91991854,012-103,441
Cashflow From Financing5798.5%92,828-1,62937,46097,4713,265-6,173211,38921,165105,313405-2,4922,91229,04467,324-687500264,347114,827-81.0043.00106,868
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

RVNC Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue, net$ 51,936$ 45,774
Operating expenses:  
Selling, general and administrative68,91461,920
Research and development14,39317,532
Amortization545545
Total operating expenses98,76392,484
Loss from continuing operations(46,827)(46,710)
Interest income2,9962,970
Interest expense(5,256)(4,497)
Other expense, net(438)(234)
Net loss from continuing operations(49,525)(48,471)
Net loss from discontinued operations(3,627)(11,322)
Total net loss(53,152)(59,793)
Unrealized gain (loss)(39)249
Comprehensive loss$ (53,191)$ (59,544)
Basic and diluted net loss per share:  
Basic net loss Continuing operations (in dollars per share)$ (0.54)$ (0.60)
Diluted net loss Continuing operations (in dollars per share)(0.54)(0.60)
Basic net loss Discontinued operations (in dollars per share)(0.04)(0.14)
Diluted net loss Discontinued operations (in dollars per share)(0.04)(0.14)
Total net loss per basic (in dollars per share)(0.58)(0.74)
Total net loss per diluted (in dollars per share)$ (0.58)$ (0.74)
Basic weighted-average number of shares used in computing net loss per share (in shares)91,919,01881,134,111
Diluted weighted-average number of shares used in computing net loss per share (in shares)91,919,01881,134,111
Product revenue, net  
Revenue:  
Total revenue, net$ 51,719$ 45,658
Operating expenses:  
Cost of product revenue (exclusive of amortization)14,91112,487
Collaboration revenue  
Revenue:  
Total revenue, net$ 217$ 116

RVNC Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
CURRENT ASSETS  
Cash and cash equivalents$ 132,609$ 137,329
Restricted cash, current550550
Short-term investments144,463116,586
Accounts receivable, net29,88727,660
Inventories50,28045,579
Prepaid expenses and other current assets9,2879,308
Current assets of discontinued operations2,6101,853
Total current assets369,686338,865
Property and equipment, net17,50517,225
Intangible assets, net8,7259,270
Operating lease right-of-use assets70,24553,167
Finance lease right-of-use asset019,815
Restricted cash, non-current5,8955,995
Finance lease prepaid expense35,84632,383
Other non-current assets217321
Non-current assets of discontinued operations01,413
TOTAL ASSETS508,119478,454
CURRENT LIABILITIES  
Accounts payable5,27613,554
Accruals and other current liabilities40,31152,863
Deferred revenue, current9,78410,737
Operating lease liabilities, current7,1265,703
Finance lease liability, current02,651
Debt, current5,0002,500
Current liabilities of discontinued operations1,4061,216
Total current liabilities68,90389,224
Debt, non-current424,838426,595
Deferred revenue, non-current71,40370,419
Operating lease liabilities, non-current38,81340,985
Other non-current liabilities2,8352,835
TOTAL LIABILITIES606,792630,058
Commitments and Contingencies (Note 12)
STOCKHOLDERS’ EQUITY (DEFICIT)  
Preferred stock, par value $0.001 per share — 5,000,000 shares authorized, and no shares issued and outstanding as of March 31, 2024 and December 31, 202300
Common stock, par value $0.001 per share — 190,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 104,409,798 and 87,962,765 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively10488
Additional paid-in capital2,032,7601,926,654
Accumulated other comprehensive gain (loss)(25)14
Accumulated deficit(2,131,512)(2,078,360)
TOTAL STOCKHOLDERS’ DEFICIT(98,673)(151,604)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT$ 508,119$ 478,454
RVNC
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
 CEO
 WEBSITErevance.com
 INDUSTRYBiotechnology
 EMPLOYEES534

Revance Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Revance Therapeutics Inc? What does RVNC stand for in stocks?

RVNC is the stock ticker symbol of Revance Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Revance Therapeutics Inc (RVNC)?

As of Fri May 17 2024, market cap of Revance Therapeutics Inc is 315.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RVNC stock?

You can check RVNC's fair value in chart for subscribers.

What is the fair value of RVNC stock?

You can check RVNC's fair value in chart for subscribers. The fair value of Revance Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Revance Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RVNC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Revance Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RVNC is over valued or under valued. Whether Revance Therapeutics Inc is cheap or expensive depends on the assumptions which impact Revance Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RVNC.

What is Revance Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, RVNC's PE ratio (Price to Earnings) is -0.99 and Price to Sales (PS) ratio is 1.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RVNC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Revance Therapeutics Inc's stock?

In the past 10 years, Revance Therapeutics Inc has provided -0.209 (multiply by 100 for percentage) rate of return.